Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Effects of Alprazolam, Buspirone and Diazepam on Daytime Sedation and Performance

  • 6 Accesses

  • 4 Citations

Summary

In a double-blind, randomised, comparative study, 44 healthy volunteers received alprazolam 0.5mg, buspirone 5mg or diazepam 5mg orally 3 times each day for 7 consecutive days. Daytime sedation was evaluated on the first and seventh treatment days by the multiple sleep latency test by direct EEG measurements. Sleep was recorded the night preceding each test day to control for the influence of sleep on subsequent daytime sedation and performance. A vigilance visual-tracking/reaction-time test was used to examine daytime performance, while other symptoms of daytime sedation were subjectively assessed by questionnaires. During treatment day 1, alprazolam- and diazepam-treated subjects were significantly sleepier than subjects who received buspirone. Compared with buspirone, performance was significantly impaired for the alprazolam subjects but not for the diazepam group. On day 7 differences in daytime sleepiness and sleep latency were no longer significant. However, alprazolam- and diazepam-treated subjects exhibited significantly slowed reaction times on the performance test. These results suggest that buspirone may have potential as an anxiolytic agent for patients in whom daytime alertness must not be compromised.

This is a preview of subscription content, log in to check access.

References

  1. Carskadon MA. Current perspectives on daytime sleepiness. Sleep 5 (Suppl.): S55–S218, 1982

  2. Carskadon MA, Dement WC. Sleep tendency: an objective measure of sleep loss. Sleep Research 6: 200, 1977

  3. Carskadon MA, Dement WC. Nocturnal determinants of daytime sleepiness. Sleep 5 (Suppl.): S73–S81, 1982

  4. Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 9: 519–524, 1986

  5. Cohn JB, Wilcox CS. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study. Journal of Clinical Psychiatry 47: 409–412, 1986

  6. Erwin CW, Linnoila M, Hartwell J, Erwin A, Guthrie S. Effects of buspirone and diazepam, alone and in combination with alcohol, on skilled performance and evoke potentials. Journal of Clinical Psychopharmacology 6: 199–209, 1986

  7. Feighner JP, Merideth CH, Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. Journal of Clinical Psychiatry 43 (12, sec. 2): 103–107, 1982

  8. Hathaway SR, McKinley JC. Booklet for the MMPI, The Psychological Corp., New York, 1970

  9. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Quantification of sleepiness: a new approach. Psychophysiology 10: 431–436, 1973

  10. Honkanen R, Ertama L, Linnoila M, et al. Role of drugs in traffic accidents. British Medical Journal 281: 1309–1312, 1980

  11. Jann MW. Buspirone: an update on a unique anxiolytic agent. Pharmacotherapy 8: 100–116, 1988

  12. Lader M. Long-term anxiolytic therapy: the issue of drug withdrawal. Journal of Clinical Psychiatry 48 (Suppl.): 12–16, 1987

  13. Lumley M, Roehrs T, Asker D, Zorick F, Roth T. Ethanol and caffeine effects on daytime sleepiness/alertness. Sleep 10: 306–312, 1987

  14. Mellinger GD, Balter MB, Uhlenhuth EH. Anti-anxiety agents: duration of use and characteristics of users in the USA. Current Medical Research and Opinion 8 (Suppl.): 21–36, 1984a

  15. Mellinger GD, Balter MB, Uhlenhuth EH. Prevalence and correlates of the long-term regular use of anxiolytics. Journal of the American Medical Association 251: 375–379, 1984b

  16. Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ. Review of the side-effect profile of buspirone. American Journal of Medicine 80(3B): 17–21, 1986

  17. Oster G, Russell MW, Huse DM, Adams, SF, Imbimbo J. Accident- and injury-related health-care utilization among benzodiazepine users and non-users. Journal of Clinical Psychiatry 48 (Suppl.): 17–21, 1987

  18. Rakel RE. Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. Southern Medical Journal 83: 194–198, 1990

  19. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton U. Psychotropic drug use and the risk of hip fracture. New England Journal of Medicine 316: 363–369, 1987

  20. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques, and scoring system for sleep stages of human subjects. Brain Information Service/Brain Research Institute, UCLA, 1968

  21. Richardson GS, Carskadon MA, Orav EJ, Dement WC. Circadian variation of sleep tendency in young and elderly adult subjects. Sleep 5 (Suppl. 2): S82–S94, 1982

  22. Roehrs T, Zwyghuizen-Doorenbos A, Timms V, Zorick F, Roth T. Sleep extension, enhanced alertness and the sedating effects of ethanol. Pharmacology, Biochemistry and Behavior 34: 321–324, 1989

  23. Roth T, Hartse KM, Zorick FJ, Kaffeman ME. The differential effects of short- and long-acting benzodiazepines upon nocturnal sleep and daytime performance. Arzneimittel Forschung 30: 891–894, 1980

  24. Seidel WF, Ball S, Cohen SA, Patterson N, Yost D, et al. Daytime alertness in relation to mood, performance, and nocturnal sleep in chronic insomniacs and non-complaining sleepers. Sleep 7: 230–238, 1984

  25. Seidel WF, Cohen SA, Bliwise NG, Dement WC. Buspirone: an anxiolytic without sedative effect. Psychopharmacology 87: 371–373, 1985a

  26. Seidel WF, Cohen SA, Bliwise NG, Roth T, Dement WC. Dose-related effects of triazolam and flurazepam on a circadian rhythm insomnia. Clinical Pharmacology and Therapeutics 40: 314–320, 1986

  27. Seidel WF, Cohen SA, Dement WC. Effects of alprazolam and diazepam on daytime sedation and performance. Psychopharmacology 87: 194–197, 1985b

  28. Seidel WF, Dement WC. Sleepiness in insomnia: evaluation and treatment. Sleep 5 (Suppl. 2): S182–S190, 1982

  29. Skegg DCG, Richards SM, Doll R. Minor tranquillisers and road accidents. British Medical Journal 1: 917–919, 1979

  30. Skolnick P, Paul SM, Weissman BA. Preclinical pharmacology of buspirone hydrochloride. Pharmacotherapy 4: 308–314, 1984

  31. Smiley A. Effects of minor tranquilizers and antidepressants on psychomotor performance. Journal of Clinical Psychiatry 48: 22–28, 1987

  32. Speilberger DC, Gorsuch RL, Lushene RE. STAI Manual for the state-trait anxiety inventory. Consulting Psychologist Press, Palo Alto, 1970

  33. USP DI. Alprazolam. In Drug information for the health care professional, 10th ed., Vol IA, p. 602, U.S. Pharmacopeial Convention Inc, Rockville, 1990

  34. USP DI. Buspirone. In Drug information for the health care professional, 10th ed., Vol IA, p. 741, U.S. Pharmacopeial Convention Inc, Rockville, 1990

  35. USP DI. Diazepam. In Drug information for the health care professional, 10th ed., Vol IA, p. 606, U.S. Pharmacopeial Convention Inc, Rockville, 1990

  36. Zwyghuizen-Doorenbos A, Roehrs T, Lamphere J, Zorick F, Roth T. Increased daytime sleepiness enhances ethanol’s sedative effects. Neuropsychopharmacology 1: 279–286, 1988

Download references

Author information

Correspondence to Dr Wesley F. Seidel.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Dement, W.C., Seidel, W.F., Cohen, S.A. et al. Effects of Alprazolam, Buspirone and Diazepam on Daytime Sedation and Performance. Drug Invest. 3, 148–156 (1991). https://doi.org/10.1007/BF03259556

Download citation

Keywords

  • Diazepam
  • Daytime Sleepiness
  • Buspirone
  • Alprazolam
  • Drug Invest